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ロミプロスチムを使用した難治性乳児免疫性血小板
減少症(ITP)の1例
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We report a case of a male infant with refractory immune thrombocytopenia (ITP) treated with romiplostim.
The patient had received intravenous immunoglobulin (IVIg) therapy for ITP since the age of 3 months, but
was hospitalized for recurrent thrombocytopenia.
On admission, there was no mucous membrane bleeding. Bone marrow examination, revealed increased
megakaryocytes and characteristic findings of ITP. Because oral prednisolone and IVIg had no effect, we decided
on observation. However, as he grew, his risk of bleeding for injury increased. We decided to use either a throm-
bopoietin (TPO) receptor agonist or rituximab. There are few reports of infants receiving TPO receptor agonists,
but there are reports of infant deaths after used rituximab, and the remission rate with TPO receptor agonists is
better than with rituximab. Therefore, we administered romiplostim, a TPO receptor agonist. We started romi-
plostim 2 months after ITP recurrence. His platelet count increased to 1×104/μL at 6 weeks after the start of
therapy, and reached 20×104/μL without further treatment at 2 years after relapse. We assume his ITP is in re-
mission.
Use of a TPO receptor agonist may be an effective non-operative treatment in refractory infantile ITP.



















出生歴：在胎 37 週 4 日，出生時体重 2,520 g，正常
分娩で出生，仮死なし．
予防接種歴：生後 2か月よりHib，PCV，ロタ，
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Table　1　Laboratory findings on admission
＜Complete blood count＞ ＜BM examination＞
WBC 10,500 /μL NCC 19.5×104 /μL
RBC 380×104 /μL Megakaryocyte 234 /μL
Hb 10.5 g/dL Myelogram
Ht 31 % blasts 0.2 %
Plt 1.3×104 /μL promyeloytes 1 %
MPV 10.0 fL (8.2-12.8) myelocyte 7 %
metamyelocyte 5 %
Thrombopoietin 0.63 fmol/mL band form 11.2 %
segment neutrophils 7.4 %
H. pylori stool antigen test (－) eosinophils 2.8 %
proerythroblasts 0 %
CMV antigen (C7-HRP): basophilic erythroblast 2.6 %
Positive cell 1 / Whole cell 50,000 polyphilic erythroblast 4.4 %
orthophilic erythroblast 13.8 %
Abdominal ultrasonography: monocyts 8.6 %









数 28.1×104/μL に回復したため，入院 8日目に退院
となった．退院 5日目より左肩に点状出血再出現し，





入院時現症：体重 6.8 kg，身長 64.9 cm，体温














入院後経過（Fig. 1）：入院 2日目に血小板 0.7×
104/μL と低下したため，IVIg 1 g/kg を施行した．入
院 5日目に血小板数 4.4×104/μL に増加したが，再
び，1.4×104/μL に減少し，トラネキサム酸の内服を













回量 1 μg/kg で投与を開始し，血小板数 5～20×
104/μL でのコントロールを目標に徐々に増量した．
投与 6週目頃より血小板数 1×104/μL 台を維持し







































































し，最大 2 mg/kg まで増量し，安全性と有効性を検
証中）．成人を対象とした臨床試験での寛解率は海外
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